The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Discussions focused on digital health, non-communicable diseases, resilient supply chains, medical innovation, and healthcare workforce development
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Lifts full-year outlook as obesity drug boom accelerates
Subscribe To Our Newsletter & Stay Updated
